Status:
COMPLETED
Physiology of GIP(1-30)NH2 in Humans
Lead Sponsor:
University Hospital, Gentofte, Copenhagen
Conditions:
Glucose Metabolism Disorders
Eligibility:
MALE
20-30 years
Phase:
NA
Brief Summary
Glucose-dependent insulinotropic polypeptide (GIP) is a gut-derived incretin hormone that affects glucose, lipid and bone metabolism. Secretion of GIP into the blood stream from enteroendocrine cells ...
Eligibility Criteria
Inclusion
- Healthy men of Northern European descent
- BMI: 19-25 kg/m2
- Stable body weight (±5%) in the last three months
Exclusion
- Treatment with medication or dietary supplements that cannot be paused for 12 hours
- More than 14 units of alcohol per week or abuse of narcotics
- Established liver disease and/or plasma alanine aminotransferase (ALT) ≥3 × normal value and/or INR outside the normal range
- Renal impairment (eGFR \<60 ml/min/1.73 m2)
- Severe arteriosclerotic heart disease or severe heart failure (NYHA group III or IV)
- Low blood count (haemoglobin \<8.3 mol/l)
- Special diet or planned body weight change before the trial period
- First-degree relatives with diabetes
- Participation in other clinical experiments with medication
- Any disease/condition that the investigators estimate disturbing for the participation in the experiment
Key Trial Info
Start Date :
June 12 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 9 2019
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT04792762
Start Date
June 12 2018
End Date
June 9 2019
Last Update
March 11 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Metabolic Physiology
Hellerup, Denmark, 2900